- PathGen secures funding from East Ventures and Royal Group Indonesia.
- The investment supports PathGen’s accessible cancer diagnostic tools.
- PathGen aims to bridge the healthcare gap by offering easy-to-use genetic testing kits.
PathGen Diagnostik Teknologi, an Indonesian biotech startup, has secured funding from East Ventures and Royal Group Indonesia.
The investment will bolster PathGen’s efforts to develop affordable and accessible cancer diagnostic tools, addressing a significant healthcare gap in the country.
Cancer slayers on a mission
Currently, only 18% of healthcare facilities in Indonesia can conduct molecular cancer testing.
PathGen aims to change this by offering easy-to-use, PCR-based genetic testing kits for various cancers, including colorectal, lung, cervical, and nasopharynx cancers.
Founded in 2020, PathGen focuses on next-generation sequencing for disease diagnosis. The startup has partnered with BioFarma, an Indonesian state-owned pharmaceutical company, to produce and distribute its inaugural product.
Additionally, PathGen is developing a digital pathology and AI platform to enhance diagnosis accuracy and precision.
Venture capitalists bet on healthcare
This investment aligns with East Ventures’ recent commitment of US$30 million to a dedicated healthcare fund, announced during the 2023 Tech in Asia Conference.
The firm recognizes the potential of biotech startups like PathGen in addressing critical healthcare challenges in the region.
To read the original article: https://www.techinasia.com/east-ventures-bets-indonesias-pathgen-improve-cancer-diagnoses
